



# Preoperative range of motion and applications of continuous passive motion predict outcomes after knee arthroplasty in patients with arthritis

Chun-De Liao<sup>1,2</sup> · Jau-Yih Tsauo<sup>1</sup> · Shih-Wei Huang<sup>2,3</sup> · Hung-Chou Chen<sup>2,4,5</sup> · Yen-Shuo Chiu<sup>6</sup> · Tsan-Hon Liou<sup>2,5,7</sup>

Received: 21 July 2018 / Accepted: 19 October 2018 / Published online: 7 December 2018  
© European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA) 2018

## Abstract

**Purpose** This study evaluated the clinical efficacy of continuous passive motion (CPM) following knee arthroplasty and determined the predictors of effect sizes of range of motion (ROM) and functional outcomes in patients with knee arthritis.

**Methods** A comprehensive electronic database search was performed for randomized controlled trials (RCTs), without publication year or language restrictions. The included RCTs were analyzed through meta-analysis and risk of bias assessment. Study methodological quality (MQ) was assessed using the Physiotherapy Evidence Database (PEDro) scale. Inverse-variance weighted univariate and multivariate metaregression analyses were performed to determine the predictors of treatment outcomes.

**Results** A total of 77 RCTs with PEDro scores ranging from 6/10 to 8/10 were included. Meta-analyses revealed an overall significant favorable effect of CPM on treatment success rates [odds ratio: 3.64, 95% confidence interval (CI) 2.21–6.00]. Significant immediate [postoperative day 14; standard mean difference (SMD): 1.06; 95% CI 0.61–1.51] and short-term (3-month follow-up; SMD: 0.80; 95% CI 0.45–1.15) effects on knee ROM and a long-term effect on function (12-month follow-up; SMD: 1.08; 95% CI 0.28–1.89) were observed. The preoperative ROM, postoperative day of CPM initiation, daily ROM increment, and total application days were significant independent predictors of CPM efficacy.

**Conclusion** Early CPM initiation with rapid progress over a long duration of CPM application predicts higher treatment effect on knee ROM and function. The results were based on a moderate level of evidence, with good MQ and potential blinding biases in the included RCTs. An aggressive protocol of CPM has clinically relevant beneficial short-term and long-term effects on postoperative outcomes.

**Level of evidence** II.

**Keywords** Knee arthroplasty · Arthritis · Range of motion · Continuous passive motion · Functional outcome

## Introduction

Continuous passive motion (CPM) immediately after arthroplastic surgery is primarily advocated for its potential benefits on knee ROM and acute stay conditions [23, 24, 35]. The

effects of CPM on postoperative outcomes have been investigated through several systemic reviews and meta-analyses [15, 17, 30, 36, 41, 42, 44]. Despite controversies, CPM has been used as an adjunct therapy to the standard postoperative rehabilitation regimen, because it offers short-term benefits during acute stay [6, 17, 30, 36, 44]; however, its long-term effectiveness during postacute follow-up remains uncertain [15, 17, 30].

Most systemic reviews and meta-analyses regarding the effectiveness of CPM have included study selection or inclusion criteria with restrictions on language [15, 30, 36, 41, 42] or publication time [30, 44]. In addition, only a few reviewers have excluded studies with low methodological quality [36, 44]. Furthermore, the majority of the articles included in most systemic reviews were published in American or

Tsan-Hon Liou and Yen-Shuo Chiu equally contributed to this study.

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s00167-018-5257-z>) contains supplementary material, which is available to authorized users.

✉ Tsan-Hon Liou  
peter\_liou@s.tmu.edu.tw

Extended author information available on the last page of the article

European countries, and few trials with Asian populations have been included [15, 17, 30, 36, 41, 42, 44]; it remains unclear whether countries or patient populations influence the effects of CPM therapy. Thus, the results reported in previous systematic reviews [40] may be biased.

In clinical practice, various prescriptions of CPM are used with multiple application parameters. CPM efficacy may depend on its application protocol, and several studies have compared the effectiveness of various CPM parameters, including the CPM initiation on the postoperative day (POD), the initial ROM (i.e., the flexion arc of motion) in the CPM device, daily increment in ROM, daily usage time, and the total application duration [2, 3, 8, 28, 29]. However, the influence of CPM parameters on treatment outcomes remains unclear [15, 17, 42]; furthermore, it remains unclear whether any parameter predicts the treatment effects on postoperative knee ROM and functional outcomes. Identification of the determinants of CPM treatment outcomes may enhance postoperative rehabilitation, because early maximum ROM regain is a clear prognostic factor for functional activity [33].

Using meta-analyses and subgroup analyses, this study was aimed to evaluate the clinical efficacy of CPM after knee arthroplasty in patients with arthritis and identified differences between populations. Furthermore, we performed metaregressions to identify the predictors of the effect of CPM therapy on postoperative outcomes during hospital stay and postacute follow-up. For clinical usefulness, determining the predictors of treatment effect of CPM following arthroplasty may help clinical practitioners establish optimal rehabilitation protocols and improve treatment efficiency for arthritis.

## Materials and methods

This study was conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines [31] and was registered with the International Prospective Register of Systematic Reviews (PROSPERO, ID number: CRD42018099139). In this study, a comprehensive search for original research articles on the clinical efficacy of postoperative CPM following knee arthroplasty was conducted using the databases of Medline, PubMed, Excerpta Medica dataBASE, Cochrane Library Database, the Physiotherapy Evidence Database (PEDro), and China Academic Journals Full-Text Database and the search engine of Google Scholar. In addition, secondary sources were searched, including papers cited in the systematic review and meta-analysis studies. No restrictions were applied for the publication year and language. If English titles were not provided in non-English articles, they were translated to English using translation software (Ginger

Software, Inc.). The search was restricted to published or in-press human studies. Two reviewers (CDL and YSC) independently searched for the articles, screened studies, and extracted data. Any disagreement between the reviewers were resolved through consensus, with other team members (HCC and SWH) acting as arbiters.

## Search strategy

We used the following search terms in the Excerpta Medica dataBASE for identifying articles on CPM after knee arthroplasty and associated conditions: [“continuous passive motion” OR “CPM”] AND [“knee arthroplasty” OR “total knee replacement”] AND [“osteoarthritis” OR “gonarthritis” OR “rheumatoid arthritis”]. The detailed search formulas for each database are presented in online Table S1.

## Study selection criteria

Articles were included if they fulfilled the following criteria: (1) the trial design was a randomized control trial (RCT) with an experimental group (i.e., CPM) and a comparison control group; (2) CPM was employed as the primary treatment; (3) the control group received regular postoperative nursing care (RNC) or underwent active exercise training (AET); (4) all patients had received a diagnosis of arthritis; (5) primary outcomes included knee joint ROM (active or passive knee flexion or the full range from extension to flexion) and pain measured using a quantifiable scale such as the visual analog scale (VAS); (6) secondary outcomes included patient-reported performance-based physical function; and (7) the following application parameters could be extracted: POD of CPM initiation, initial and final ROM set, daily ROM increment, daily application time, and application duration (i.e., total application days).

Articles meeting any of the following criteria were excluded: (1) the article evaluated an animal model, a case report, or case series; (2) the study in the article was a prospectively designed trial without a comparison group; (3) the full text of the article was unavailable; and (4) the study had fair or poor methodological quality, which was identified as a PEDro score of < 6/10 [32].

## Data extraction and management

For the included studies, a data extraction sheet was developed and refined. An author (CDL) extracted the relevant data from the included studies, and another author (SWH) reviewed the extracted data. Any disagreement between the two authors was resolved through consensus. A third author (THL) was consulted if the disagreement persisted. The data of interest were group design, patient characteristics (population, age, sex, diagnosis, duration of disease onset), surgical

conditions (e.g., prosthesis used and operated leg), CPM application parameters (e.g., POD of CPM initiation, initial setting in ROM, and daily increment in ROM), and follow-up period. The primary outcome of interest in the meta-analysis and metaregression was full knee ROM. If the trial did not report full knee ROM, it was estimated by subtracting knee flexion from knee extension, and knee extension was assumed as 0° when only knee flexion was reported. If the trial reported both active and passive ROM as well as knee flexion and extension, active ROM measures were included in the analyses. Pain severity was evaluated using either the VAS or a patient-reported scale. The functional scores used by the studies were Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Society Score, and Hospital for Special Surgery Knee Scoring.

If any of the CPM application parameters were reported in terms of ranges, the medians of the ranges were used for analyses. If a study did not report any value and stated that the daily ROM increment during CPM therapy was determined according to patient tolerance, the daily ROM increment was assumed to be 15°; this value was chosen, because most of the previous protocols have used daily ROM increments of 5° to 20° [17, 30, 36, 42, 44] and it concurred with our previous results [26].

### Assessment of methodological quality

The PEDro classification scale was employed to assess the methodological quality in the included trials [10]. Any disagreement between the two researchers (CDL and HCC) was resolved through consensus, and a third researcher (THL) was consulted if the disagreement could not be resolved. On the basis of the PEDro score, the methodological quality of the included RCTs was rated as high ( $\geq 7/10$ ) or medium ( $< 7/10$ ) [5].

### Assessment of risk of bias

Two authors (CDL and HCC) independently assessed the risk of bias of the included studies using the Cochrane risk of bias tool [18, 20]. Any difference of opinion was resolved through consensus, and if necessary, any disagreement was resolved by a third reviewer (THL).

### Statistical analysis

The effect sizes of CPM on the primary and secondary outcome measures were estimated by calculating the standard mean differences (SMDs) of the mean outcome between the treatment and control groups weighted by the inverse of the variation for every included study. SMD was used for meta-analysis when different scales were used to measure the same concept (e.g., pain and function score). In accordance

with Cohen's criteria [9], we categorized the magnitude of the SMD as trivial ( $d < 0.20$ ), small ( $0.20 \leq d < 0.60$ ), moderate ( $0.60 \leq d < 1.20$ ), and large ( $d \geq 1.20$ ), which represent the categories modified by Hopkins [21]. If data were reported as a standard error or confidence interval (CI), they were recalculated algebraically from the trial data for imputing the sample mean and SD following the Cochrane Handbook for Systematic Reviews of Interventions [20]. The odds ratio (OR) with a 95% CI was estimated to indicate treatment success. Statistical heterogeneity of the included studies was assessed using the  $Q$  test ( $\chi^2$ ) and  $I^2$  statistics, with high values indicating high heterogeneity [4]. If the study had more than one CPM or control intervention, each comparison was considered as an independent one for the meta-analyses [19]. Random-effects models were used for the meta-analyses. The effects of CPM on primary and secondary outcomes during hospital acute stay ( $\leq 2$  weeks) and postacute follow-up ( $> 1$  month) were separately analyzed. All meta-analyses were conducted using RevMan 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark).

Subgroup analysis was performed on the basis of the population area, follow-up duration, methodological design, and quality level. The significance of all subgroup differences was assessed, and  $I^2$  statistics were computed to estimate the degree of subgroup variability. Potential publication bias was investigated through the visual inspection of a funnel plot [39] and through Egger's regression asymmetry test [13].

Following a previously described method [5], we graded levels of evidence (LoE) for each outcome of interest in accordance with an evidence synthesis guideline [12] derived from van Tulder's criteria [43] (Table 1).

To determinate the significant predictors of CPM efficacy for primary and secondary outcomes, inverse-variance weighted univariate and multivariate metaregression was performed using SPSS (version 17; IBM, Armonk, New York, USA). The mean age, body mass index, preoperative ROM as well as function, CPM application parameters, intervention design, control-group type, and follow-up duration were entered as covariates. First, univariate linear regression analyses were separately performed for each covariate at acute stay and postacute follow-up. To determine significant parameters, all CPM application parameters were then included in a stepwise multivariate regression analysis as covariates; the analysis was controlled for age, methodological design, preoperative ROM, and follow-up duration.

## Results

### Trial flow

The search yielded 916 articles (Fig. 1). After duplicate article removal and abstract screening, 160 eligible RCTs

**Table 1** Guidelines of evidence synthesis


| Level of evidence | Criterion of judgment  |
|-------------------|--|
| Strong            | Provided by consistent <sup>a</sup> statistically significant (or nonsignificant) pooled results in SMD or OR derived from multiple RCTs, including at least two high-quality RCTs <sup>b</sup>  |
| Moderate          | Provided by statistically significant results in one high-quality RCT <sup>b</sup> <b>or</b><br>Provided by inconsistent <sup>a</sup> statistically significant pooled results in SMD or OR derived from multiple RCTs, including at least one high-quality RCT <sup>b</sup> <b>or</b>   |
| Limited           | Provided by consistent <sup>a</sup> statistically significant pooled results in SMD or OR derived from multiple medium-quality RCTs <sup>b</sup><br>Provided by statistically significant results in one medium-quality RCT <sup>b</sup> <b>or</b><br>Provided by inconsistent <sup>a</sup> statistically significant pooled results in SMD or OR derived from multiple RCTs, including at least one medium-quality RCT <sup>b</sup> |
| Conflicting       | Provided by inconsistent <sup>a</sup> statistically nonsignificant results in SMD or OR derived from multiple RCTs regardless of quality   |

RCT randomized controlled trial, SMD standard mean difference, OR odds ratio

Established in accordance with the “best-evidence synthesis,” adapted by Dorrestijn et al. [12] from van Tulder’s criteria [43]

<sup>a</sup>Pooled results are considered consistent if no statistically significant heterogeneity ( $I^2$ ,  $P > 0.05$ ) is identified and inconsistent if statistically significant  $I^2$  ( $P < 0.05$ ) is identified

<sup>b</sup>Methodological quality of a study is rated based on PEDro score as high ( $\geq 7/10$ ) and medium ( $< 7/10$ )



**Fig. 1** PRISMA flow chart of randomized controlled trials enrolled in the meta-analysis study

were identified for full-text assessment. The final sample comprised 77 RCTs, which included 93 comparisons between CPM group and the control group receiving RNC or AET. Characteristics of the included RCTs are presented in Table S2 and are summarized in Table 2.

## Study characteristics

In total, 6038 patients with mean ages ranging from 52.0 to 74.2 years (overall mean age 65.7 years). These patients experienced symptoms for a mean duration of 110.2 months (range 4–264 months). The 77 RCTs included populations from Americas (709 patients), Asia (4395 patients), Europe (692 patients), and Oceania (144 patients) (Table 2).

CPM application parameters and treatment protocols are summarized in Table S3. All included RCTs applied a CPM intervention protocol that was initiated on POD 0–14 with an initial flexion ROM of 30°–90°, a daily ROM increment of 5°–20° as tolerable by patients, a daily application time of 0.5–12 h, and an intervention duration of 1–21 days.

## Risk of bias in the included studies

A summary of the PEDro scores of the included RCTs is presented in Table 3. The individual PEDro scores and the rated quality levels are listed in Tables S4 and S2, respectively. Regarding the cumulative PEDro score, interrater reliability was acceptable, and the intraclass correlation coefficient was 0.97 (95% CI 0.95–0.98,  $P < 0.001$ ). Of the included RCTs, 20.8% and 79.2% were classified as high and medium, respectively, with an overall mean (range/total) PEDro score of 6.4 (6–8/10). The risk of bias as assessed using the Cochrane Collaboration risk of bias tool (Fig. S1) was generally low or unclear. An overall summary of the risk of bias among the included RCTs is presented in Fig. 2. Selection, blinding, attrition, and agenda biases were considered the greatest potential risks of bias in the included RCTs.

**Table 2** Summary of study characteristics

| Items  | CPM intervention        |           |              | Control                 |           |              | Total                   |              |                   |
|--|-------------------------|-----------|--------------|-------------------------|-----------|--------------|-------------------------|--------------|-------------------|
|  | Trials (n) <sup>a</sup> | Group (n) | Patients (n) | Trials (n) <sup>a</sup> | Group (n) | Patients (n) | Trials (n) <sup>b</sup> | Patients (n) | Mean <sup>b</sup> |
| Age, years   | 49                      | 61        | 1971         | 49                      | 51        | 1792         | 76                      | 5936         | 65.4              |
| BMI, kg/m <sup>2</sup>                                 | 12                      | 16        | 551          | 12                      | 12        | 411          | 12                      | 992          | 29.1              |
| Onset time, mo   | 6                       | 9         | 370          | 6                       | 6         | 208          | 11                      | 971          | 77.2              |
| Sex, n   |                         |           |              |                         |           |              |                         |              |                   |
| Male   | 46                      | 58        | 1189         | 46                      | 48        | 1061         | 74                      | 3626         |                   |
| Female   | 46                      | 58        | 700          | 46                      | 48        | 656          | 74                      | 2159         |                   |
| Population area  |                         |           |              |                         |           |              |                         |              |                   |
| Americas   | 9                       | 13        | 344          | 9                       | 11        | 365          | 9                       | 709          |                   |
| Asia   | 56                      | 64        | 2297         | 56                      | 56        | 2098         | 56                      | 4395         |                   |
| Europe   | 10                      | 10        | 339          | 10                      | 10        | 353          | 10                      | 692          |                   |
| Oceania  | 2                       | 3         | 144          | 2                       | 2         | 98           | 2                       | 242          |                   |
| Arthroplasty type                                      |                         |           |              |                         |           |              |                         |              |                   |
| TKA  | 75                      | 88        | 2089         | 75                      | 77        | 2881         | 77                      | 6030         |                   |
| UKA  | 1                       | 1         | 5            | 1                       | 1         | 3            | 1                       | 8            |                   |
| Operated knee, n                                       |                         |           |              |                         |           |              |                         |              |                   |
| Unilateral   | 60                      | 70        | 4082         | 60                      | 62        | 2137         | 65                      | 4284         |                   |
| Bilateral  | 9                       | 11        | 60           | 9                       | 9         | 54           | 14                      | 207          |                   |
| Diagnosis, n   |                         |           |              |                         |           |              |                         |              |                   |
| OA   | 53                      | 65        | 2077         | 53                      | 55        | 1908         | 77                      | 5452         |                   |
| RA   | 11                      | 11        | 111          | 11                      | 11        | 106          | 30                      | 511          |                   |
| Others <sup>c</sup>                                    | 3                       | 3         | 11           | 3                       | 4         | 11           | 12                      | 75           |                   |
| Preoperative ROM, degree                               | 40                      | 47        | 1675         | 40                      | 42        | 1588         | 61                      | 4834         | 85.2              |
| Preoperative function                                  |                         |           |              |                         |           |              |                         |              |                   |
| WOMAC  | 7                       | 9         | 334          | 7                       | 7         | 282          | 7                       | 616          | 49.3              |
| KSS Function   | 7                       | 8         | 425          | 7                       | 7         | 395          | 7                       | 820          | 48.8              |
| HSS  | 21                      | 21        | 831          | 21                      | 21        | 814          | 26                      | 1645         | 48.8              |
| Methodological design Intervention design Control type |                         |           |              |                         |           |              |                         |              |                   |
| Monotherapy CPM  | 36                      | 45        | 1507         |                         |           |              | 36                      | 1507         |                   |
| RNC control  |                         |           |              | 22                      | 22        | 857          | 22                      | 857          |                   |
| AET control  |                         |           |              | 17                      | 18        | 559          | 17                      | 559          |                   |
| Adjuvant therapy                                       | 41                      | 45        | 1617         |                         |           |              | 41                      | 1609         |                   |
| RNC control  |                         |           |              | 12                      | 12        | 423          | 12                      | 423          |                   |
| AET control  |                         |           |              | 29                      | 30        | 1083         | 29                      | 1083         |                   |

TKA total knee arthroplasty, UKA unicompartmental knee arthroplasty, BMI body mass index, OA osteoarthritis, RA rheumatoid arthritis, WOMA Western Ontario and McMaster Universities Osteoarthritis Index, KSS Knee Society Score, HSS Hospital for Special Surgery Knee Scoring, RNC regular postoperative nursing care, AET active exercise training

<sup>a</sup>Number of trials reporting the indicated item

<sup>b</sup>Summations were calculated based on the values reported in the included trials, where it can be estimated

**Table 3** Summary of methodological quality crossing the included trials

| Rated item <sup>a</sup>        | Quality level (PEDro score) |                            |
|--------------------------------|-----------------------------|----------------------------|
|                                | High (≥ 7/10, 16 RCTs)      | Medium (< 7/10, 61 RCTs)   |
|                                | Trials, n (%) <sup>b</sup>  | Trials, n (%) <sup>b</sup> |
| Eligibility criteria           | 16 (100)                    | 52 (85.2)                  |
| Random allocation              | 16 (100)                    | 61 (100)                   |
| Concealed allocation           | 12 (75)                     | 0 (0)                      |
| Similarity at the baseline     | 16 (100)                    | 61 (100)                   |
| Participant blinding           | 0 (0)                       | 0 (0)                      |
| Therapist blinding             | 0 (0)                       | 0 (0)                      |
| Assessor blinding              | 11 (68.8)                   | 2 (3.3)                    |
| Adequate follow-up             | 16 (100)                    | 61 (100)                   |
| Intention-to-treat analysis    | 15 (93.8)                   | 59 (96.7)                  |
| Between-group comparison       | 16 (100)                    | 61 (100)                   |
| Point and variability measures | 16 (100)                    | 61 (100)                   |

*PEDro* Physiotherapy Evidence Database, *RCT* randomized control trial

Individual PEDro scores are listed in online supplementary Table S4 and the rated quality levels are shown in Table S2

<sup>a</sup>Details of each item and guidelines of rating criteria are available from the Physiotherapy Evidence Database (<https://www.pedro.org.au/english/downloads/pedro-scale/>)

<sup>b</sup>Percentage of the same quality level

**Publication bias**

Visual inspection of the funnel plots of ROM regain did not reveal substantial asymmetry (Fig. 3). In addition, Egger’s

linear regression test provided no evidence of reporting bias among the trials (n.s.).

**Meta-analyses**

**Treatment success rates and general outcomes**


Treatment success rates (TSRs) for pain severity and global outcomes were mostly assessed using a Likert scale [7, 34] (Table S2). In the overall follow-up duration, the CPM group had a higher TSR than the non-CPM or active control group in the random-effects model (OR 3.64,  $P < 0.00001$ ; LoE, moderate; Fig. S2).

**Effect of CPM on postoperative pain**

During acute stay, SMDs for pain reduction after CPM therapy were observed from POD 3 (SMD = -0.87,  $P = 0.005$ ) to POD 14 (SMD = -0.70,  $P = 0.002$ ) without significant heterogeneity among follow-up time frames ( $I^2 = 0\%$ ) (Fig. S3), and an overall SMD of -0.96 ( $P < 0.0001$ ; LoE, moderate) favoring CPM was observed (Fig. S4).


During postacute follow-up, SMDs were observed only for short-term effects on pain reduction at 1-month follow-up (SMD = -0.56,  $P = 0.01$ ), favoring CPM; there was significant difference in heterogeneity among time frame subgroups ( $I^2 = 64\%$ ) (Fig. S5). In the overall postacute follow-up duration, a significant SMD of -0.64 favoring CPM ( $P = 0.005$ ; LoE, moderate) was observed (Fig. S6).

**Fig. 2** Risk of bias summary across the included randomized controlled trials





**Fig. 3** Publication bias plot. Funnel plot for effect size of knee ROM. The SMDs of knee ROM is plotted on the x-axis and standard error of SMD is plotted on the y-axis. The vertical dotted line indicates the mean value of the SMDs. Visual inspection of the funnel plot of the SMDs of pain score did not reveal substantial asymmetry. Egger’s linear regression test results indicated no evidence of reporting bias among the studies (n.s.). ROM range of motion, SMD standard mean difference



**Effect of CPM on range of motion**


The meta-analysis for knee ROM during acute hospital stay revealed that irrespective of the application protocol and methodological design, CPM significantly improved knee ROM on POD 5 with an SMD of 0.75 ( $P=0.001$ ); similar results were observed on POD 10 and POD 14 (Fig. 4 and Table S5) and no significant heterogeneity among time frames was observed during acute stay (Fig. S7).

During postacute follow-up, significant effects on knee ROM were only observed at 3-month follow-up (SMD = 0.80,  $P < 0.00001$ ; LoE, moderate) (Fig. 4 and Table S6); however, no significant heterogeneity was observed among time frames (Fig. S8).

**Effect of CPM on functional outcome**

During acute stay, the effect of CPM on pooled functional scores was significant with an SMD of 1.59 ( $P=0.03$ ) on POD 5, and similar results were observed on POD 10 and POD 14, irrespective of the application protocol and methodological design (Fig. 4 and Table S5); however, significant differences were observed among time frames during acute stay ( $I^2=79.2%$ ) (Fig. S9).

Similar results were observed at 3-month (SMD = 0.86,  $P < 0.00001$ ), 6-month (SMD = 1.02,  $P = 0.004$ ), and 12-month (SMD = 1.08,  $P = 0.009$ ) follow-up (Fig. 4 and Table S6); no significant differences were observed among time frames during postacute follow-up ( $I^2=0%$ ) (Fig. S10).



**Fig. 4** Forest plot of CPM therapy. Subgroup analyses for knee range of motion and functional recovery during the follow-up periods. Subgroup results plotted on the right-hand side indicate effects favoring CPM, and the combined effects are plotted using black diamonds.

CI confidence interval, IV inverse variance, Random random-effects model, CPM continuous passive motion, POD postoperative day, PEDro Physiotherapy Evidence Database, RNC regular nursing care, AET active exercise training

## Subgroup analysis

During acute stay, all kinds of subgroups, except CPM intervention designs during all acute stay time frames, showed significant group differences in knee ROM as well as function (Fig. 4 and Table S5).

During postacute follow-up, significant differences in knee ROM effect were observed between the quality-level, population-area, control-type, and intervention-design subgroups at 3-month follow-up only (Fig. 4 and Table S6). At 3-month and 12-month follow-ups, significant differences in knee function effect was also observed in quality-level and population subgroups.

## Metaregression analysis

### Determinants of CPM efficacy


Young age ( $R^2 = 18.9\%$ ,  $P = 0.001$ ), low BMI ( $R^2 = 30.3\%$ ,  $P = 0.04$ ), and less preoperative ROM ( $R^2 = 20.3\%$ ,  $P = 0.006$ ) predicted greater effect sizes of knee ROM, pain, and functional outcomes during acute stay (Table S7); similar results were observed in knee ROM at postacute follow-up (Table S8). After all time frames were pooled, patients with a preoperative ROM of  $< 100^\circ$  achieved a positive effect size of knee ROM following postoperative CPM therapy ( $\beta = -0.05$ ; 95% CI  $-0.07, -0.03$ ;  $P < 0.001$ ) (Fig. 5).

Regarding CPM application parameters, a greater daily ROM increment ( $R^2 = 47.5\%$ ,  $P < 0.001$ ) and longer duration of CPM application ( $R^2 = 18.3\%$ ,  $P = 0.003$ ) significantly predicted larger effect sizes of postoperative ROM and functional recovery during acute stay (Table S7). At postacute follow-up, CPM application parameters had no effect on outcomes, except that an earlier POD of CPM initiation ( $R^2 = 9.9\%$ ,  $P = 0.048$ ) significantly predicted greater function recovery (Table S8). In addition, the POD of CPM initiation ( $R^2 = 22.7\%$ ,  $P = 0.02$ ) and daily ROM increment ( $R^2 = 61.6\%$ ,  $P < 0.001$ ) were also predictors of the effect size of treatment success.

The control type and CPM intervention design were significantly associated with the effect sizes of knee ROM at acute stay and postacute follow-up, respectively (Tables S7 and S8); similar results were observed in knee function. Follow-up duration was not associated with effect sizes of outcomes at acute stay and postacute follow-up (Tables S7 and S8).

### CPM application parameters are associated with CPM efficacy

Four iterations of multiple linear regressions were performed for data analysis (Table 4). After controlling for patient characteristics and methodological designs, greater daily ROM increment and early POD of CPM initiation independently predicted greater effect sizes of postoperative knee ROM; similar results were found for function and treatment success.



**Fig. 5** Multivariate metaregression between preoperative ROM and effects of CPM on knee ROM. Each circle represents an independent comparison. The size of each circle is proportional to that study's weight (inverse-variance weighted). The regression prediction is represented by the solid line for effect size (SMD) of knee ROM

( $\beta = -0.05$ ; 95% CI  $-0.07$  to  $-0.03$ ;  $P < 0.001$ ). Dotted lines represent the 95% CI. The metaregression model was adjusted for age, methodological design and quality, and follow-up time of each comparison. CPM continuous passive motion, ROM range of motion



## Discussion

The meta-analyses provided statistically significant moderate evidence supporting that CPM increased the TSR, reduced pain, restored the knee ROM, and enhanced functional recovery, regardless of the follow-up duration, application parameters, and methodological design. We further identified that patient's age and preoperative ROM significantly influenced the effect size of knee ROM after CPM therapy; in addition, CPM application parameters including POD of CPM initiation and daily ROM increment independently predicted effects on knee ROM and function.

In this meta-analysis, there was moderate evidence supporting that CPM exerted not only short-term benefits on postoperative knee ROM which is in line with previous systemic reviews [15, 36, 42, 44] but also long-term (12 months) effects on knee function which is conflicting to the previous results [17, 30, 41]. Unlike previous systemic reviews [15, 17, 30, 36, 41, 42, 44], in the current meta-analysis, RCTs without restrictions on publication year or language were selected, comparatively more RCTs with Asian populations were included, and RCTs with low methodological quality were excluded. The differences in the study selection and inclusion criteria may have contributed to the inconsistency between our results and previous systemic reviews.

Older age, knee stiffness, and obesity are risk factors for poor postoperative ROM [1, 14, 16, 22, 37] and rehabilitation outcomes during hospital acute stay and postacute follow-up [25–27]. In the present study, the results indicated that a lower preoperative ROM of  $< 100^\circ$  can be predicted to achieve a positive effect size of knee ROM after CPM; this result is consistent with a previous study result indicating that patients with stiff knees before TKA surgery may experience greater gain in knee ROM postoperatively compared with those without knee stiffness [45].

The results of this meta-analysis revealed that CPM application parameters, particularly the POD of CPM initiation, daily ROM increment, and total days of application, were independent determinants of CPM clinical efficacy. Our findings are supported by previous studies [15] but are inconsistent with a recent Cochrane analysis [17]. It is believed that CPM demonstrated positive biologic effects on tissue healing, edema, hemarthrosis, and joint function [6, 35, 38]. Therefore, CPM may exert the greatest benefit with early initiation, greater progress in motion arc, and longer duration of application during acute hospital stay.

Several limitations of this study must be considered. First, although the data did not suggest substantial publication bias, heterogeneity was observed among the included RCTs, which may be attributed to the varying methodological designs and application protocols. Second, the nature of

**Table 4** Association of CPM application parameters with knee joint ROM and function outcome at discharge and postacute follow-up

| Covariate                                      | Model 1 <sup>†</sup> |          | Model 2 <sup>§</sup> |          |
|--|----------------------|----------|----------------------|----------|
|  | $\beta$              | SE       | $\beta$              | SE       |
| Dependent variable = Treatment success (ln OR) |                      |          |                      |          |
| Daily ROM increment ( $^\circ$ )               | 0.092                | 0.013*** | 0.095                | 0.016*** |
| CPM-initiated POD ( <i>days</i> )              | -0.494               | 0.205*   | -0.515               | 0.347    |
| Adjusted $R^2$                                 | 0.765                |          | 0.760                |          |
| Model $P$ value                                | 0.026                |          | n.s                  |          |
| Comparison, $n$                                | 22                   |          | 22                   |          |
| Dependent variable = Knee ROM (SMD)            |                      |          |                      |          |
| Daily ROM increment (degree)                   | 0.047                | 0.013**  | 0.037                | 0.012**  |
| CPM-initiated POD (days)                       | -0.192               | 0.081*   | -0.254               | 0.075**  |
| Adjusted $R^2$                                 | 0.374                |          | 0.570                |          |
| Model $P$ value                                | 0.023                |          | 0.007                |          |
| Comparison, $n$                                | 40                   |          | 38                   |          |
| Dependent variable = Knee function (SMD)       |                      |          |                      |          |
| Daily ROM increment (degree)                   | 0.070                | 0.015*** | 0.119                | 0.022*** |
| Application duration (days)                    | 0.106                | 0.023*** | 0.037                | 0.052    |
| Adjusted $R^2$                                 | 0.591                |          | 0.681                |          |
| Model $P$ value                                | <0.001               |          | n.s                  |          |
| Comparison, $n$                                | 50                   |          | 24                   |          |

ROM range of motion, CPM continuous passive motion, POD postoperative day, ln OR natural log transformed odds ratio, SMD standard mean difference

\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$

<sup>†</sup>Model 1: Stepwise linear regression variables included parameters of CPM application. The linear model coefficients were represented as  $\beta$  values with standard error (SE)

<sup>§</sup>Model 2: Stepwise linear regression variables included age, population area, preoperative ROM, intervention design, comparison type, follow-up duration, and variables from model 1. Population area was coded as Americas=1, Asia=2, Europe=3, and Oceania=4. Intervention design was coded as monotherapy=1 and adjunctive therapy=2; comparison type was coded as regular care=1 and active exercise control=2

CPM intervention led to a high risk of blinding biases; however, all the included RCTs had good methodological quality (PEDro score  $\geq 6$ ). Finally, other confounding factors such as disease duration, surgery technique, prosthesis design, and postdischarge rehabilitation, which may have contributed to treatment efficacy [11], were not assessed when analyzing effect sizes of ROM and functional outcomes.

In this study, the clinically relevant results were identified that patient characteristics influenced the treatment effects of CPM therapy; in addition, an aggressive protocol of CPM application may predict greater treatment effects on postoperative outcomes. Such results may help clinical practitioners establish prompt and efficient rehabilitation protocols after knee arthroplasty in arthritis patients, especially for

those with older age, higher BMI, and poor preoperative ROM.

## Conclusion

In this study, we provided moderate evidence indicating that postoperative CPM therapy exerted significant short-term effects on TSR, pain, and knee ROM and a long-term effect on functional recovery in patients with arthritis. In addition, patient characteristics and CPM applications may influence treatment efficacy. Owing to potential biases (blinding biases) in the included RCTs of this study, we recommend that CPM should be cautiously applied to achieve favorable postoperative outcomes.

**Funding** This study was funded by grants from Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, Taiwan (grant no. W107HCP-04). The funding source had no role in the design, implementation, data analysis and interpretation, or reporting of the study. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of the funding sources.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest related to the publication of this article.

**Ethical approval** This study dealt with published data only, no ethical approval has been necessary since sensitive information has not been provided or utilized in this review.

## References

- Alzahrani K, Gandhi R, Debeer J, Petruccioli D, Mahomed N (2011) Prevalence of clinically significant improvement following total knee replacement. *J Rheumatol* 38(4):753–759
- Basso DM, Knapp L (1987) Comparison of two continuous passive motion protocols for patients with total knee implants. *Phys Ther* 67(3):360–363
- Bennett LA, Brearley SC, Hart JA, Bailey MJ (2005) A comparison of 2 continuous passive motion protocols after total knee arthroplasty: a controlled and randomized study. *J Arthroplasty* 20(2):225–233
- Bowden J, Tierney JF, Copas AJ, Burdett S (2011) Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. *BMC Med Res Methodol* 11:41–53
- Briani RV, Ferreira AS, Pazzinato MF, Pappas E, De Oliveira Silva D, Azevedo FM (2018) What interventions can improve quality of life or psychosocial factors of individuals with knee osteoarthritis? A systematic review with meta-analysis of primary outcomes from randomised controlled trials. *Br J Sports Med* 52(16):1031–1038
- Brosseau L, Milne S, Wells G, Tugwell P, Robinson V, Casimiro L et al (2004) Efficacy of continuous passive motion following total knee arthroplasty: a metaanalysis. *J Rheumatol* 31(11):2251–2264
- Carifio J, Perla RJ (2007) Ten common misunderstandings, misconceptions, persistent myths and urban legends about likert. *J Soc Sci* 3(3):106–116
- Chiarello CM, Gundersen L, O'Halloran T (1997) The effect of continuous passive motion duration and increment on range of motion in total knee arthroplasty patients. *J Orthop Sports Phys Ther* 25(2):119–127
- Cohen J (1988) The analysis of variance. In: *Statistical power analysis for the behavioral sciences*, 2nd edn. Lawrence Erlbaum Associates, Hillsdale, pp 273–406
- de Morton NA (2009) The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. *Aust J Physiother* 55(2):129–133
- Dennis DA, Komistek RD, Scuderi GR, Zingde S (2007) Factors affecting flexion after total knee arthroplasty. *Clin Orthop Relat Res* 464:53–60
- Dorrestijn O, Stevens M, Winters JC, van der Meer K, Diercks RL (2009) Conservative or surgical treatment for subacromial impingement syndrome? A systematic review. *J Shoulder Elbow Surg* 18(4):652–660
- Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315(7109):629–634
- Farahini H, Moghtadaei M, Bagheri A, Akbarian E (2012) Factors influencing range of motion after total knee arthroplasty. *Iran Red Crescent Med J* 14(7):417–421
- Grella RJ (2008) Continuous passive motion following total knee arthroplasty: a useful adjunct to early mobilisation? *Phys Ther Rev* 13(4):269–279
- Harvey IA, Barry K, Kirby SP, Johnson R, Elloy MA (1993) Factors affecting the range of movement of total knee arthroplasty. *J Bone Joint Surg Br* 75(6):950–955
- Harvey LA, Brosseau L, Herbert RD (2014) Continuous passive motion following total knee arthroplasty in people with arthritis. *Cochrane Database Syst Rev* 2:CD004260
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 343:d5928
- Higgins JPT, Deeks JJ, Altman DG (2011) Chapter 16: special topics in statistics. In: Higgins JPT, Green S (eds) *Cochrane handbook for systematic reviews of interventions version 5.1.0* [updated March 2011]: the cochrane collaboration. <http://handbook.cochrane.org>. Accessed Jun 04, 2018
- Higgins JPT, Green S (2011) *Cochrane handbook for systematic reviews of interventions version 5.1.0* [updated March 2011]. The cochrane collaboration. <http://handbook.cochrane.org>. Accessed Jun 04, 2018
- Hopkins WG (2002) A scale of magnitudes for effect statistics: a new view of statistics. <http://sportssci.org/resource/stats/effectmag.html>. Accessed Jun 04, 2018
- Jarvenpaa J, Kettunen J, Kroger H, Miettinen H (2010) Obesity may impair the early outcome of total knee arthroplasty. *Scand J Surg* 99(1):45–49
- Johnson DP, Eastwood DM (1992) Beneficial effects of continuous passive motion after total condylar knee arthroplasty. *Ann R Coll Surg Engl* 74(6):412–416
- Lachiewicz PF (2000) The role of continuous passive motion after total knee arthroplasty. *Clin Orthop Relat Res* 380:144–150
- Liao CD, Huang YC, Chiu YS, Liou TH (2017) Effect of body mass index on knee function outcome following continuous passive motion in patients with osteoarthritis after total knee replacement. *Physiotherapy* 103(3):266–275
- Liao CD, Huang YC, Lin LF, Chiu YS, Tsai JC, Chen CL et al (2016) Continuous passive motion and its effects on knee flexion after total knee arthroplasty in patients with knee osteoarthritis. *Knee Surg Sports Traumatol Arthrosc* 24(8):2578–2586

27. Liao CD, Huang YC, Lin LF, Huang SW, Liou TH (2015) Body mass index and functional mobility outcome following early rehabilitation after a total knee replacement: a retrospective study in taiwan. *Arthr Care Res (Hoboken)* 67(6):799–808
28. MacDonald SJ, Bourne RB, Rorabeck CH, McCalden RW, Kramer J, Vaz M (2000) Prospective randomized clinical trial of continuous passive motion after total knee arthroplasty. *Clin Orthop Relat Res* (380):30–35
29. Maniar RN, Baviskar JV, Singhi T, Rathi SS (2012) To use or not to use continuous passive motion post-total knee arthroplasty presenting functional assessment results in early recovery. *J Arthroplasty* 27(2):193–200 e1
30. Mayo BS, Rodriguez-Mansilla J, Sanchez BG (2015) Recovery from total knee arthroplasty through continuous passive motion. *An Sist Sanit Navar* 38(2):297–310
31. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 4:1
32. Moseley AM, Herbert RD, Sherrington C, Maher CG (2002) Evidence for physiotherapy practice: a survey of the physiotherapy evidence database (PEDro). *Aust J Physiother* 48(1):43–49
33. Naylor JM, Ko V, Rougellis S, Green N, Mittal R, Heard R et al (2012) Is discharge knee range of motion a useful and relevant clinical indicator after total knee replacement? Part 2. *J Eval Clin Pract* 18(3):652–658
34. Norman G (2010) Likert scales, levels of measurement and the “laws” of statistics. *Adv Health Sci Educ Theory Pract* 15(5):625–632
35. O’Driscoll SW, Giori NJ (2000) Continuous passive motion (CPM): theory and principles of clinical application. *J Rehabil Res Dev* 37(2):179–188
36. Postel JM, Thoumie P, Missaoui B, Biau D, Ribinik P, Revel M et al (2007) Continuous passive motion compared with intermittent mobilization after total knee arthroplasty. Elaboration of French clinical practice guidelines. *Ann Readapt Med Phys* 50(4):244–257
37. Ritter MA, Harty LD, Davis KE, Meding JB, Berend ME (2003) Predicting range of motion after total knee arthroplasty. Clustering, log-linear regression, and regression tree analysis. *J Bone Joint Surg Am* 85-A(7):1278–1285
38. Salter RB (1989) The biologic concept of continuous passive motion of synovial joints. The first 18 years of basic research and its clinical application. *Clin Orthop Relat Res* (242):12–25
39. Sedgwick P, Marston L (2015) How to read a funnel plot in a meta-analysis. *BMJ* 351:1–3
40. Sterne JAC, Egger M, Moher D (2011) Chapter 10: addressing reporting biases. In: Higgins JPT, Green S (eds) *Cochrane handbook for systematic reviews of interventions* version 5.1.0 [updated March 2011]. The cochrane collaboration. <http://www.handbook.cochrane.org>. Accessed 12 Oct 2018
41. Tedesco D, Gori D, Desai KR, Asch S, Carroll IR, Curtin C et al (2017) Drug-free interventions to reduce pain or opioid consumption after total knee arthroplasty: a systematic review and meta-analysis. *JAMA Surg* 152(10):e172872
42. van Dijk HJD, Elvers JWH, Ruijter A, Oostendorp RAB (2007) Effect of continuous passive motion after total knee arthroplasty: a systematic review. *Phys Singap* 10(4):9–19
43. van Tulder M, Furlan A, Bombardier C, Bouter L (2003) Updated method guidelines for systematic reviews in the cochrane collaboration back review group. *Spine (Phila Pa 1976)* 28(12):1290–1299
44. Viswanathan PKM (2010) Effect of continuous passive motion following total knee arthroplasty on knee range of motion and function: a systematic review. *New Zeal J Physiother* 38(3):14–22
45. Winemaker M, Rahman WA, Petruccioli D, de Beer J (2012) Pre-operative knee stiffness and total knee arthroplasty outcomes. *J Arthroplasty* 27(8):1437–1441

## Affiliations

Chun-De Liao<sup>1,2</sup> · Jau-Yih Tsauo<sup>1</sup> · Shih-Wei Huang<sup>2,3</sup> · Hung-Chou Chen<sup>2,4,5</sup> · Yen-Shuo Chiu<sup>6</sup> · Tsan-Hon Liou<sup>2,5,7</sup>

<sup>1</sup> School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan

<sup>2</sup> Department of Physical Medicine and Rehabilitation, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan

<sup>3</sup> Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan, Taiwan

<sup>4</sup> Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan

<sup>5</sup> Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei, Taiwan

<sup>6</sup> Department of Orthopedics, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan

<sup>7</sup> Graduate Institute of Injury Prevention and Control, Taipei Medical University, Taipei, Taiwan